Pharmaceuticals
Hanmi Pharmaceutical's Combination Drug for Dyslipidemia Treatment, 'Rosuzet': Confirmed Non-inferiority Efficacy and Safety Compared to Monotherapy in 'The Lancet' & 'European Heart Journal'
SEOUL, South Korea, March 17, 2023 /PRNewswire/ -- Hanmi Pharmaceuticals (128940.KS), a subsidiary of Hanmi Science (008930.KS) in Korea, announced that the results of large-scale clinical trial with Rosuzet have been published in 'The Lancet' and the 'European Heart Journal'. R&D-oriented pha...
2023-03-17 21:00
4888
Samsung Biologics announces construction of Plant 5 to commence Bio Campus II capacity expansion
* The company plans to begin construction in the first half of 2023 and commence operations in 2025 * As part of Samsung Biologics' second Bio Campus, Plant 5 will hold a manufacturing capacity of 180,000 liters, expanding the company's total site capacity to 784,000 liters upon its completio...
2023-03-17 19:25
4211
China's first personalized neoantigen-targeted cancer vaccine receives NMPA's clinical trial approval
BEIJING, March 17, 2023 /PRNewswire/ -- According the latest data released at the Clinical Trials Implied Approval section on the website ofChina's Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA), Likang Life Sciences (hereinafter referred to as "Likang") h...
2023-03-17 14:56
2754
YS BIOPHARMA TO RING THE OPENING BELL AND DEBUT ON NASDAQ
YS Biopharma Ordinary Shares and Warrants to Trade on the Nasdaq Under Tickers "YS" and "YSBPW" NEW YORK, March 17, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (the "Company" or "YS Biopharma"), a global biopharmaceutical company focusing on new generations of vaccines and therapeutic biologic...
2023-03-17 04:30
3166
Nav1.7 Selective Inhibitor OLP-1002 Shows Strong Efficacy and Long Therapeutic Duration according to Interim Findings from a Phase 2a Study in OA Patients
SEOUL, South Korea, March 16, 2023 /PRNewswire/ -- OliPass Corporation, an RNA therapeutics platform company, disclosed that OLP-1002, a selective inhibitor of Nav1.7 sodium ion channel, showed strong analgesic efficacy and long therapeutic duration according to interim findings from a placebo-co...
2023-03-16 21:00
2557
FDA Approves Expanded Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Directed Radioligand Therapy
INDIANAPOLIS, March 16, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the United States Food and Drug Administration (FDA) has approved a supplementary New Drug Application (sNDA) for Illuccix® (kit for the preparation of gallium Ga 68 goze...
2023-03-16 20:28
2627
Bolstering Healthcare Quality in Malaysia with Renowned Flagship Hospitals
Malaysia's position as a safe and trusted destination for high-quality healthcare services is reinforced with the debut of flagship medical tourism hospitals in the country. KUALA LUMPUR, Malaysia, March 16, 2023 /PRNewswire/ -- Malaysia has debuted its first-of-its-kind Flagship Medical Tourism...
2023-03-16 16:12
6185
The FDA has approved the CSF-1R inhibitor Pimicotinib (ABSK021) of Abbisko Therapeutics to enter the Pivotal Global Multi-center Phase III Clinical Trial
This is the first-ever global phase III trial for TGCT approved by NMPA and FDA. Pimicotinib（ABSK021）was granted BTD by FDA and CDE, discovered and developed byChina biotech。 SHANGHAI, March 16, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. (HKEX Stock Code: 2256. HK, referred to as "Abbis...
2023-03-16 10:00
5911
Alphamab Oncology Announces the First Patient Dosed in the Phase I Trial of Anti-HER2 bispecific ADC JSKN003
SUZHOU, China, March 16, 2023 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been dosed with 2.1mg/kg in a Phase I clinical study (JSKN003-102) of JSKN003, an Anti-HER2 bispecific ADC. ADC drugs have the advantages of highly specific targeting of anti...
2023-03-16 09:58
3481
FDA Approves Expanded Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Directed Radioligand Therapy
MELBOURNE, Australia, March 16, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the United States Food and Drug Administration (FDA) has approved a supplementary New Drug Application (sNDA) for Illuccix® (kit for the preparation of gallium Ga...
2023-03-16 08:28
3315
Akeso Reported 2022 Annual Results
* Strong sales fully demonstrated Akeso's commercialization ability: Products sales totaledRMB1,104.4 million, increasing 422% .开坦尼® (cadonilimab) recorded strong sales ofRMB546.3 million in its first six months of approval in China. 安尼可®(penpulimab injection, PD-1) recorded product sales ofRMB...
2023-03-16 08:26
5273
Ark Biopharmaceutical and Calibr, a Division of Scripps Research, Announce Co-development Collaboration on AK0705, a Potential First-in-Class Drug for Treating a Broad Spectrum of Respiratory Diseases, Including COPD
* Ark Biopharmaceutical will lead development activities for AK0705 with the goal of initiating clinical studies in 2024. * Calibr will continue to collaborate in the development of AK0705. * The collaboration is an extension of the current co-development collaboration. SHANGHAI, March 16, 2...
2023-03-16 07:50
5129
Bridge Biotherapeutics to Present Updated Preclinical Data of BBT-207 at the AACR 2023 Annual Meeting
* The abstract of BBT-207 preclinical studies is now available on the AACR
website
2023-03-15 21:00
3221
Everest Medicines to Announce Full-Year 2022 Financial Results on March 31, 2023
SHANGHAI, March 15, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, today announced that it will report financial results for the full year endedDecember 31, 20...
2023-03-15 20:45
3751
HanAll Biopharma Opens Applications for the 2023 Pharmaceutical Industry Fellowship Program
* Applications for physicians trained in Indonesia now open until April 15, 2023 12:00 AM * The Pharmaceutical Industry Fellowship Program provides physicians with the opportunity to experience the various steps of the drug development process ROCKVILLE, Md. and SEOUL, South Korea, March 15, ...
2023-03-15 19:00
2868
Nippon Express (Belgium) Joins Pharma.Aero
TOKYO, March 15, 2023 /PRNewswire/ -- Nippon Express (Belgium) N.V./S.A. (hereinafter "NX Belgium"), a group company of NIPPON EXPRESS HOLDINGS, INC., became the first Japanese forwarder to join Pharma.Aero (*) onJanuary 25 this year. Pharma.Aero logo: https://kyodonewsprwire.jp/img/202303033576...
2023-03-15 14:00
2287
Jacobio Pharma to Present Data of Three Preclinical Studies at the 2023 AACR Annual Meeting
BEIJING and SHANGHAI and BOSTON, Mass., March 14, 2023 /PRNewswire/ -- Jacobin Pharma (1167.HK) today announced that the company will present the results of three preclinical studies of KRASmulti inhibitor JAB-23425, CD73-STING iADC JAB-X1800, and Aurora kinase A inhibitor JAB-2485 in form of the...
2023-03-15 10:45
3955
Alphamab Oncology to Present the Preclinical Results of PD-L1/OX40 Bispecific Antibody KN052 at AACR 2023
SUZHOU, China, March 15, 2023 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the preclinical result of KN052 (PD-L1/OX40 bispecific antibody) is accepted as Late-Breaking Research in 114th Annual Meeting of the American Association for Cancer Research (AACR 2023). The res...
2023-03-15 10:06
3569
Ascentage Pharma to Present Latest Results from Three Preclinical Studies at 2023 American Association for Cancer Research Annual Meeting
SUZHOU, China and ROCKVILLE, Md., March 14, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the latest results from three preclinical s...
2023-03-15 07:59
3737
YS BIOPHARMA AND SUMMIT HEALTHCARE ANNOUNCE SHAREHOLDER APPROVAL OF BUSINESS COMBINATION
* Business Combination to deliver approximately $36 million of gross proceeds * YS Biopharma expects to close the Business Combination on March 16, 2023 * YS Biopharma Ordinary Shares and YS Biopharma Warrants expected to begin trading on the Nasdaq onMarch 17, 2023 under the symbols "YS" and...
2023-03-15 04:01
4803
Week's Top Stories
Most Reposted
Visa and Marina Bay Precinct Partners - Marina Bay Sands, UOB and Singapore Tourism Board - Present 'A Moment to Savour', Bringing International Restaurant Collaborations to Singapore
[Picked up by 310 media titles]
2026-10-27 13:40
Agoda becomes first travel platform regionally to seamlessly connect with Meta's Muse
[Picked up by 294 media titles]
2026-10-28 09:00
Hong Leong Bank Strengthens Cross-Border Payment Connectivity through Partnership with UnionPay International
[Picked up by 294 media titles]
2026-10-28 12:12
OneQode Signs 14 MW AI Capacity Agreement with AdaniConneX, with a Path to 114 MW
[Picked up by 277 media titles]
2026-10-28 09:00
Pepperstone and Aston Martin Aramco extend and expand partnership with Fernando Alonso appointed Global Ambassador from 2027.
[Picked up by 276 media titles]
2026-10-29 13:01
Most Read
SwitchBot Launches AI Art Frame 2 with Full-Color E Ink and Personalized Art
2026-10-27 21:00
45457
The Future of AI 3D Character Workflows: Reallusion CC 5.2 Turns Meshes into Living Characters
2026-10-29 20:03
20938
ROKAE delivers its 10,000th humanoid force-controlled arm
2026-10-27 00:00
18441
